Dawit Zemichael
Psychiatry · Athens, TNNPI 1164511317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 135 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 34.2% of the total. Reporting peaked in 2019 at $784 and has fallen 76.2% since, to $186 in 2025.
Across 135 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$652
- Neurocrine Biosciences, Inc.$257
- Sunovion Pharmaceuticals Inc.$215
- Axsome Therapeutics, Inc.$200
- AbbVie$168
- Ironshore Pharmaceuticals Inc.$82
- plus $332 from 12 others
What the payments were for
- Speaking & faculty fees$241%
- Food & beverage$1,88099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 52 | $652 |
| Neurocrine Biosciences, Inc. | 14 | $257 |
| Sunovion Pharmaceuticals Inc. | 21 | $215 |
| Axsome Therapeutics, Inc. | 11 | $200 |
| AbbVie(2 entities) | 11 | $168 |
| Ironshore Pharmaceuticals Inc. | 4 | $82 |
| Indivior Inc. | 3 | $65 |
| Lundbeck LLC | 5 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $47 |
| Johnson & Johnson | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $26 |
| Almatica Pharma LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
| Orexo US, Inc. | 1 | $15 |
| Neuronetics, Inc. | 1 | $15 |
| Corium, LLC | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,904 in reported general payments places this provider in the 75th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 13 | $21,771 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 63 | $10,057 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $9,605 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 35 | $1,407 |
| Gabapentin | 36 | $601 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $258 |
| Eszopiclone | 26 | $257 |
| Alprazolam | 35 | $128 |
| Hydroxyzine Hcl | 12 | $78 |
| Clonazepam | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $65 | $9,60517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Athens
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- John FenleyJohnson City$1.4M
- David SnowMaryville$605K
- Karthi NamasivayamKnoxville$225K
- Robert JamiesonNashville$141K
- George BrownJohnson City$91K
- Sricharan MoturiFranklin$82K
- Michelle CochranNashville$74K
- Daniel BoydMemphis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.